TABLE 3.
PHARMACOKINETIC PARAMETERS FOLLOWING I.V AND INTRANASAL ADMINISTRATION OF RB-LOADED TTM NANOEMULSION AND GEL FORMULATIONS
| Parameters | Route | Plasma | Brain |
|---|---|---|---|
| Cmax (ng/ml g) | i.n.(nano) | 7806.137±613.2a | 2954±255.6 |
| i.n.(gel) | 7702.915±657.1 | 670±60.7 | |
| i.v. | 7847.500±657.1 | 597±60.7 | |
| Tmax (min) | i.n.(nano) | 15 | 30 |
| i.n.(gel) | 15 | 30 | |
| i.v. | 15 | 30 | |
| AUC0→240 | i.n.(nano) | 1707290±2789 | 302520±2475 |
| (ng min/ml g) | i.n.(gel) | 1732516±3935 | 115000±3821 |
| i.v. | 1800538±3134 | 109627.5±3014 | |
| Ratio of AUCi.n./AUCi.v.(%) | i.n.(nano) | 94.84b | 275.95 |
| i.n. (gel) | 96.22b |
i.v.: RB solution; i.n. (nano) RB nanoemulsion; i.n. (gel) RB-gel
a
Mean±SD (n=3-4)
b
bioavailability.